Trial
NCT00073008
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Lung Cancer, Non-Small Cell
Intervention
GW572016 (lapatinib)
Why stopped
Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-28